Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing

Background: A fixed dose of 200 mg of pembrolizumab every 3 weeks (Q3W) is the standard of care for patients with stage IV non-small cell lung cancer (NSCLC) and PDL1 ≥50%. In April 2020, based on pharmacokinetic modeling without formal comparative studies, the FDA approved 400 mg every 6 weeks (Q6W...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Lauren Jones, Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-11-01
Edice:	Current Oncology
Témata:	PDL1 pembrolizumab dosing schedule NSCLC
On-line přístup:	https://www.mdpi.com/1718-7729/29/11/685
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!